Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough

Rodriguez, Alejandro; Lisboa, Thiago; Blot, Stijn; Martin-Loeches, Ignacio; Solé-Violan, Jorge; De Mendoza, Diego; Rello, Jordi
March 2009
Intensive Care Medicine;Mar2009, Vol. 35 Issue 3, p430
Academic Journal
It remains uncertain why immunocompetent patients with bacterial community-acquired pneumonia (CAP) die, in spite of adequate antibiotics. This is a secondary analysis of the CAPUCI database which was a prospective observational multicentre study. Two hundred and twelve immunocompetent patients admitted to 33 Spanish ICUs for CAP were analyzed. Comparisons were made for lifestyle risk factors, comorbidities and severity of illness. ICU mortality was the principal outcome variable. Bacteremic CAP (43.3 vs. 21.1%) and empyema (11.5 vs. 2.2%) were more frequent ( P < 0.05) in patients with Streptococcus pneumoniae CAP. Higher rates of adequate empiric therapy (95.8 vs. 75.5%, P < 0.05) were observed in patients with S. pneumoniae CAP. Patients with non-pneumococcal CAP experienced more shock (66.7 vs. 50.8%, P < 0.05), and need for mechanical ventilation (83.3 vs. 61.5%, P < 0.05). ICU mortality was 20.7 and 28% [OR 1.49(0.74–2.98)] among immunocompetent patients with S. pneumoniae ( n = 122) and non-pneumococci ( n = 90), in spite of initial adequate antibiotic. Multivariable regression analysis in these 184 immunocompetent patients with adequate empirical antibiotic treatment identified the following variables as independently associated with mortality: shock (HR 13.03); acute renal failure (HR 4.79), and APACHE II score higher than 24 (HR 2.22). Mortality remains unacceptably high in immunocompetent patients admitted to the ICU with bacterial pneumonia, despite adequate initial antibiotics and comorbidities management. Patients with shock, acute renal failure and APACHE II score higher than 24 should be considered for inclusion in trials of adjunctive therapy in order to improve CAP survival.


Related Articles

  • Bacteremic Streptococcus pneumoniae in Community-Acquired Pneumonia: An Update. Herrero, Francisco Sanz; Pérez, Tomás Lloret; Olivas, José Blanquer // Current Respiratory Medicine Reviews;2010, Vol. 6 Issue 3, p188 

    Invasive pneumococcal disease is a major cause of morbimortality worldwide. The presence of bacteremia in pneumococcal pneumonia constitutes an additional factor of worse prognosis, although the highest virulence of invasive pneumococcal infection is clustered in certain serotypes. Antibiotic...

  • Synergistic effect of cefixime and cloxacillin combination against common bacterial pathogens causing community acquired pneumonia. Agarwal, Astha; Jain, N.; Jain, A. // Indian Journal of Pharmacology;Oct2007, Vol. 39 Issue 5, p251 

    The article reports on the findings of the study which examines the synergistic effect of cloxacillin and cefixime against the common pathogens causing community acquired pneumonia (CAP). In the study, the researchers tested the combinations of cloxacillin and cefixime against different...

  • The Urinary Antigen Tests have High Sensitivity in Diagnosis of Pneumococcus Caused Community-Acquired Pneumonia Posterior to Antimicrobial Therapy. Chen, Ming; Zhou, Ming; Xiao, Wei; Ai, Biao; Liu, Xuezheng; Li, Yan // Cell Biochemistry & Biophysics;Nov2014, Vol. 70 Issue 2, p1029 

    Antibiotic treatment before microbiological test significant reduces the positive rate of culture methods of Streptococcus pneumoniae. The Binax NOW S. pneumoniae immunochromatographic test (ICT) has become a more commonly used procedure to diagnose S. pneumoniae from community-acquired...

  • Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. Fogarty, Charles M.; Patel, Tushar C.; Dunbar, Lala M.; Leroy, Bruno P. // BMC Infectious Diseases;2005, Vol. 5 Issue 1, p43 

    Background: Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality throughout the world. Telithromycin (a new ketolide) has shown good in vitro activity against the key causative pathogens of CAP, including S pneumoniae resistant to penicillin and/or macrolides....

  • Basilea Shares Rise As Ceftobiprole Snags EU Approval. Sheridan, Cormac // BioWorld Today;10/24/2013, Vol. 24 Issue 205, p1 

    The article reports on the seven percent increase in Basilea Pharmaceutica AG's shares in October 2013. The increase is attributed to the approval received by its broad spectrum cephalosporin antibiotic ceftobiprole in Europe for treatment of hospital- and community-acquired pneumonia adults....

  • Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. Thomas M. File; Lionel A. Mandell; Glenn Tillotson; Kosta Kostov; Ognian Georgiev // Journal of Antimicrobial Chemotherapy (JAC);Jun2007, Vol. 60 Issue 1, p112 

    Objectives Short-course therapy has been advocated for the treatment of community-acquired pneumonia (CAP). We compared the efficacy and safety of 5 and 7 day courses of gemifloxacin for outpatient treatment of mild–moderate CAP. Patients and methods In a multicentre, double-blind,...

  • Narrow-spectrum agents noninferior to broad-spectrum agents for CAP. Queen, Mary Ann // Infectious Diseases in Children;Jan2014, Vol. 27 Issue 1, p9 

    The article discusses a study by Doctor Mary Ann Queen from Children's Mercy Hospital and Clinics in Kansas City, Missouri which found that patients treated with narrow-spectrum antibiotics for community-acquired pneumonia (CAP) had similar outcomes to children treated with broad-spectrum agents.

  • Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community-Acquired Pneumonia. Pertel, Peter E.; Bernardo, Patricia; Fogarty, Charles; Matthews, Peter; Northland, Rebeca; Benvenuto, Mark; Thorne, Grace M.; Luperchio, Steven A.; Arbeit, Robert D.; Alder, Jeff // Clinical Infectious Diseases;4/15/2008, Vol. 46 Issue 8, p1142 

    Objective. We sought to compare daptomycin with ceftriaxone for the treatment of patients with communityacquired pneumonia (CAP). Methods. Two phase-3 randomized, double-blind trials that enrolled adult patients hospitalized with CAP were conducted. Patients received intravenous daptomycin (4...

  • Current Key Points in Management for Severe Community-Acquired Pneumonia. Martin-Loeches, Ignacio; Lisboa, Thiago; Rello, Jordi // Current Respiratory Medicine Reviews;2011, Vol. 7 Issue 4, p250 

    Community-acquired pneumonia (CAP) is not a homogeneous entity. S. pneumoniae is the most prevalent pathogen associated with severe CAP and is responsible for two-thirds of CAP-related deaths. Today, there is a need for effective strategies to develop and establish the optimum dosage regimen of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics